Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Research
Return to: PBR Home | Contract Research & Services | Contract Research | Suppliers

Almac Group Announce £27 million Global Expansion

Published 10 November 2016 | By Almac

Almac Group, the global contract pharmaceutical development and manufacturing organisation is excited to announce ambitious plans to expand its operations in Europe and North America increasing its global headcount to reach 5,000 by 2017

As part of its ongoing global growth strategy and in response to increased client demand for its range of services the organisation will invest a further £20 million at Almac's US headquarter site in Souderton, Pennsylvania to expand its existing 240,000-square-foot facility in addition to leasing a 26,000-square-foot office space in nearby Lansdale.

The expansion project will create 312 new, full time jobs across a wide range of functions and increases capabilities for its Sciences, Clinical Services, Clinical Technologies and Pharma Services businesses. The company received a funding proposal from the Department of Community and Economic Development comprised of a £1.3 million Pennsylvania First Program grant and involves substantial investment in new machine lines, computer equipment, software and an expanded cold storage area.

The company is also investing in the region of £5 million to build an additional laboratory and office facility at its global headquarters site in Craigavon, Northern Ireland. Around 170 existing employees will be transferred to the new building, many of whom are chemists and analysts involved in supporting drug research, development and manufacture.

An additional £2 million is being invested in the development of the Arran Chemical Company facility in Athlone, Ireland which was acquired by Almac last year. The capital project is enabling an upgrade of the existing site infrastructure and brings additional manufacturing capacity and assets on stream as well as more distillation and drying capabilities. Together, the expansion plans facilitates significant growth of the Almac Sciences business, which is vital to meet ongoing demand for its innovative API and chemical development services, with global headcount within this Business Unit alone expected to reach over 500 by next year - more than double its figure just three years ago.

In total, the Almac Group employs over 4,600 staff globally and is set to reach 5,000 by the end of 2017.

Secretary Dennis M. Davin from the Pennsylvanian Department of Community and Economic Development announced Almac's plans during a visit to its North American Headquarter facility on Thursday 10th November. This announcement comes just weeks after the company announced a £4.2 million expansion at its facility in North Carolina.

Governor of Pennsylvania, Tom Wolf welcomed the news:

In 2007, Almac Group invested $100 million, retained 495 jobs, and created another 264 jobs, when it successfully established its U.S. headquarters in Pennsylvania.

Since then, we've seen Almac Group's significant contributions to the economic vitality of the region as a major player in south-eastern Pennsylvania's strong bio-pharma industry, and we look forward to its continued success as it once again chooses Pennsylvania for its operations expansion.

Alan Armstrong, CEO Almac Group commented:

Due to significant industry demand for our services it is essential we build capacity and increase headcount to ensure we continue to compete at a global level. This year we are celebrating our twentieth year in the US and we are excited to make a further commitment within the Pennsylvania State and throughout North America. We are also delighted to announce our further expansion plans across Europe as we continue to build upon our tremendous global success and we are looking forward to an exciting future.


About Almac Group
'Partnering to Advance Human Health'

The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally. The services range from R&D, biomarker discovery development and commercialisation, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.

The international company is a privately owned organisation that has organically grown over 40 years and now employs in excess of 4,500 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations in the UK, Ireland, across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo).

https://www.almacgroup.com